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Abstract: In the past years, genome wide association studies (GWAS) have provided evidence
that inter-individual susceptibility to diverse pathological conditions can reveal a common genetic
architecture. Through the analysis of congenital heart disease (CHD) and neuroblastoma (NB) GWAS
data, we aimed to dissect the genetic susceptibility shared between these conditions, which are known
to arise from neural crest cell (NCC) migration or development abnormalities, via identification and
functional characterization of common regions of association. Two loci (2q35 and 3q25.32) harbor
single nucleotide polymorphisms (SNPs) that are associated at a p-value < 10−3 with conotruncal
malformations and ventricular septal defect respectively, as well as with NB. In addition, the lead SNP
in 4p16.2 for atrial septal defect and the lead SNP in 3q25.32 for tetralogy of Fallot are less than 250 Kb
distant from the lead SNPs for NB at the same genomic regions. Some of these shared susceptibility
loci regulate the expression of relevant genes involved in NCC formation and developmental processes
(such as BARD1, MSX1, and SHOX2) and are enriched in several epigenetic markers from NB and fetal
heart cell lines. Although the clinical correlation between NB and CHD is unclear, our exploration of
a possible common genetic basis between NB and a subset of cardiac malformations can help shed
light on their shared embryological origin and pathogenetic mechanisms.
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1. Introduction
Neuroblastoma (NB) is an embryonic tumor arising from the sympathetic nervous tissue and is
among the most frequent cancers diagnosed in early infants, accounting for 13% of all deaths due to
childhood malignancies [1]. Its etiology is due to an overgrowth in the sympathetic ganglion where
neural crest derived progenitors reside. Whereas familial NB is rare [2], sporadic NB has a higher
incidence: The study of its genetic susceptibility can therefore benefit from a more abundant cohort
of patients and has thus been largely investigated by means of genome wide association studies
(GWAS) [3,4] and candidate gene approaches [5–7].
Congenital heart disease (CHD) is one of the most frequent inborn disorders in infants, affecting
7 in 1000 live births and is a major cause of childhood death and long term morbidity [8]. Complex
genetic mechanisms underlie cardiac development and its anomalies, and a number of different defects
could be the cause—such as migration defects, reduced specification or overproduction of neural
crest-derived mesenchymal cell types—and efforts have been made to try and elucidate causative
variants affecting these conditions [9–12].
Neural crest cells (NCC) development and migration abnormalities have been conjectured to be
implicated in the genesis of both CHD and NB [13–16], and there are case reports in the literature
of patients affected with both of these conditions simultaneously [17]. George and colleagues [18]
demonstrated that children affected with NB have a higher prevalence of CHD; however, van Engelen
and colleagues [19] have denied evidence of association between these two conditions. A review of
more than 1900 cases showed that NBs account for approximately 17% of the malignancies seen in
Costello and Noonan syndromes [20], a disorder characterized by diverse tissue and organ defects,
including CHD [21]. Lombardo and colleagues [22] very recently reported an association between
CHD and mutations in PHOX2B, a susceptibility gene for familial NB [23]. In spite of some negative
evidence, it is possible that NB and CHD share susceptibility loci but that their phenotypes are not
highly penetrant in individuals with certain susceptible mutations.
Demonstrating a correlation between NB and CHD could provide useful information to patients
suffering from these conditions, including the opportunity of specific genetic counseling addressing the
possible onset of the other disease. Although epidemiological studies are a powerful tool for addressing
this question, genome wide association studies (GWAS) can provide a deeper level of understanding
of the genetics underlying phenotypic traits, including pathological conditions. The accumulation of
large-scale genomic datasets has led to the detection of novel loci associated with diverse traits and
enhanced the study of shared genetic factors across phenotypes, but a thorough characterization of
these identified loci would be advisable, both at the genetic and epigenetic level. Using data from
different conditions can reveal the presence of common genetic risk factors and shared causal pathways,
thus improving our understanding of disease.
Given NB and CHD common embryological derivation from NCC [21,24], we analyzed GWAS
results for these traits in order to evaluate the extent of shared genetics between NB and seven CHD
conditions: atrial septal defect/patent foramen ovale (ASD/PFO), conotruncal malformations (CM),
double outlet right ventricle (DORV), left-sided malformations (LH), transposition of the great arteries
(TGA), tetralogy of Fallot (ToF), and ventricular septal defect (VSD).
2. Materials and Methods
2.1. Neuroblastoma GWAS Summary Statistics
GWAS summary statistics were taken from the work of McDaniel and colleagues [25]. These refer
to a European-American cohort of 2101 cases and 4202 matched controls (Table 1) assayed with Illumina
HumanHap550 v1, HumanHap550 v3, and Human610 single nucleotide polymorphism (SNP) arrays.
Genotype phasing was performed using SHAPEIT v2.r790 [26] and data from 1000 Genomes Phase 1
Release 3. Subsequent imputation was performed genome-wide using IMPUTE2 v2.3.1 [27] for all
SNPs and indel variants annotated in 1000 Genomes Phase 1 Release 3. Only SNPs with minor allele
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frequency (MAF) >0.01 and info score >0.8 were considered. Manhattan plot of the NB GWAS is
available in Figure S1 and characteristics of patients are summarized in Table S1.
Table 1. Data sets used in this study.
Condition Cases Controls
ASD/PFO 340 5159
CM 151 5159
DORV 96 5159
LH 387 5159
NB 2101 4202
TGA 207 5159
ToF 835 5159
VSD 191 5159
Number of cases and controls for each dataset used. ASD/PFO: atrial septal defect/patent foramen ovale; CM:
conotruncal malformations; DORV: double outlet right ventricle; LH: left-sided malformations; NB: neuroblastoma;
TGA: transposition of the great arteries; ToF: tetralogy of Fallot; VSD: ventricular septal defect.
2.2. CHD Genotypes
Genotypes from 5159 controls and patients with seven different subtypes of CHD, namely atrial
septal defect/patent foramen ovale (ASD/PFO, 340 cases), conotruncal malformations (CM, 151 cases),
double outlet right ventricle (DORV, 96 cases), left-sided malformations (LH, 387 cases), transposition
of the great arteries (TGA, 207 cases), tetralogy of Fallot (ToF, 835 cases), and ventricular septal defect
(VSD, 191 cases), were those included in the work of Cordell and colleagues [9]. Manhattan plots of
the CHD GWAS are available in Figure S1.
2.3. CHD Genotypes Imputation
We used the Michigan Imputation Server [28] to perform imputation on the CHD datasets
(reference panel: 1000G Phase 3 v5).
2.4. CHD Association Analysis
Dosage vcf files from the imputation output were fed to SNPTEST v2.5.4 beta1 [29] software and
frequentist association test was used to compute summary statistics.
2.5. Evaluation of the Extent of Shared Genetics
The first step of our workflow (Figure 1) was the evaluation of the genome-wide shared genetics
between NB and CHD. To this end, we pruned the whole set of common SNPs based on linkage
disequilibrium (LD) with plink v1.9 [30] using a r2 threshold of 0.2 (plink –indep-pairwise function;
parameters used are: r2 = 0.2; window size = 500 Kb; step size = 20) in order to consider only SNPs in
approximate linkage equilibrium and evaluated the number of independent SNPs with association
p-values above and below several thresholds (0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001) in NB and in
each CHD condition. This procedure prevents the overestimation of association signals due to LD
structure (such as when multiple signals are present from high LD regions). If the two conditions do
not share a genetic basis, these values should not deviate from random expectation. A 2 × 2 table for
each p-value cutoff was created and one-sided Fisher exact tests were used as the statistical measure of
significance and strength of association. We also ran simulations to assess the validity of our results:
For each CHD condition, each SNP was randomly assigned a p-value from the list of observed p-values
deriving from the association analysis for that condition. We repeated this a thousand times, and
an empirical p-value was calculated from the proportion of simulations having a number of SNPs
below a given p-value threshold in both datasets (NB and one CHD type) greater than or equal to the
observed number of SNPs below the same p-value threshold in both real datasets (NB and one CHD
type) under consideration.
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2.6. Identification of Colocalizing Association Signals
To identify shared association signals between NB and CHD, SNPs with an association
p-value < 10−3 [31] in both NB and at least one CHD dataset were selected, and shared association signals
were defined as thos regions containing at least 10 such SNPs within distance of less than 100 Kb.
To identify possibly colocalizing but distinct associati n signals, we elected SNPs with an association
p-value < 10−5 in NB or at least one CHD dataset, and candidate regions were identified if at least 10
SNPs within a distance of less than 100 Kb were present. The threshold of p-value < 10−5 was chosen
as it corresponds to an average of 1 false-positive association per GWAS in European populations [32].
The distance between lead SNPs of these candidate regions in NB and in the CHD conditions was then
used to evaluate these potential colocalization signals deriving from distinct variants.
We also ran simulations to assess the significance of these distinct, colocalizing signals by randomly
reshuffling the location of the associated regions in our NB dataset while keeping their size fixed:
An empirical p-value was calculated from the proportion of simulations having a number of regions
less than 250 Kb distant between NB and CHD greater than or equal to the real datasets.
A method prop sed by Pickrell and c ll s [33] was also used to detect colocalizin regions.
The algorithm gen rates posterior probabiliti h a Bayesian a proach for t e hypotheses that
the region harbors one variant associated to both, to only one or to none of the traits, or that the region
contains one variant associated only to one trait and another variant associated only to the other trait.
2.7. Enrichment of Epigenetic Signatures in Susceptibility Loci
Enrichment in epigenetic features of several cell types related to neural crest cells (NCC) and heart,
and NCC derived tumors (NB and melanoma) was computed through R VSE package from CRAN [34].
Briefly, it creates a network from SNPs that accounts for LD structure and generates a null model by
sampling SNPs from a comprehensive pool of tag SNPs, thus recreating the same LD clusters as in the
real data, matching each associated variant set to a random variant set with the same characteristics.
Haploreg [35] was also used to perform enhancer enrichment analysis on sets of variants (binomial
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test), using as background frequency the overlap from 1000 Genome variants with a frequency above
5% in any population.
2.8. eQTL Analysis
LinDA [36] was used to identify genes regulated by variants of interest, as well as tissues involved.
This tool takes as input a list of variants and queries 199 datasets belonging to 53 projects, comprising
15 human populations and 33 body districts, resulting in 486,244 eQTLs and 36,768 eGenes.
3. Results
3.1. Evaluation of the Genome Wide Extent of Shared Genetic Association
To evaluate the genome-wide shared genetic signals between NB and CHD, we selected a subset
of independent SNPs in approximate linkage equilibrium with each other and evaluated for each
condition the number of SNPs with association p-value above and below different thresholds. We
used Fisher exact test and simulation analysis to evaluate whether NB and each CHD condition in
turn share more SNPs above and below the p-value thresholds than expected by chance [37] (see
Materials and Methods Section 2.5). We found some evidence of shared association signals between
NB and ASD/PFO, between NB and CM, and between NB and VSD (Table 2, Figure 2, Tables S2 and S3).
As reported in Table 2, SNPs with p-value less than 0.01 are shared more frequently than expected
between NB and all CHD datasets (Fisher exact test p-value = 0.02). Common association signals
are also observed for low p-value thresholds when considering NB and CM (<0.005; Fisher exact
p-value = 0.04) and when considering NB and VSD (<0.0005; Fisher exact p-value = 0.05) and for high
p-value thresholds when considering NB and ASD/PFO (<0.05; Fisher exact p-value = 0.02).
Table 2. Evaluation of the extent of shared genetic effects between neuroblastoma (NB) and congenital
heart disease (CHD).
Dataset p-value Threshold Fisher Test p-value Odds Ratio
ALL 0.0001 1 0
ALL 0.0005 1 0
ALL 0.001 1 0
ALL 0.005 0.92 0.46
ALL 0.01 0.02 1.56
ALL 0.05 0.84 0.94
ASD/PFO 0.0001 1 0
ASD/PFO 0.0005 1 0
ASD/PFO 0.001 1 0
ASD/PFO 0.005 0.64 0.89
ASD/PFO 0.01 0.52 1.01
ASD/PFO 0.05 0.02 1.12
CM 0.0001 1 0
CM 0.0005 1 0
CM 0.001 0.18 4.97
CM 0.005 0.04 2.05
CM 0.01 0.23 1.23
CM 0.05 0.99 0.84
VSD 0.0001 1 0
VSD 0.0005 0.05 19.45
VSD 0.001 0.15 5.86
VSD 0.005 0.27 1.43
VSD 0.01 0.53 1
VSD 0.05 0.8 0.94
The union of all CHD datasets is considered as well as the most significant subtypes from this analysis. After extracting
SNPs in approximate linkage equilibrium (r2 < 0.2) from the full set of all common SNPs (see Materials and Methods
Section 2.5 for details), for p-values ranging from 0.0001 to 0.05, Fisher exact test was performed for the SNPs above
and below p-value threshold in NB and in the given condition.
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Figure 2. Regional association plots of significant loci described in text. In blue is NB, in red are
different subtypes of CHD. (A) NB and VSD at 3q25.32, (B) NB and CM at 2q35, (C) NB and ToF at
3q25.32, (D) NB and DORV at 2q35, (E) NB and DORV at 3q25.32, (F) NB and ToF at 2q35.
3.2. Identification of Colocalizing Association Signals between NB and CHD
We defined shared association regions as genomic locations harboring at least 10 SNPs with
association p-value < 10−3 in NB and in at least one CHD subtype (see Materials and Methods
Section 2.6). With this procedure, we identified two main regions spanning over several Kb: one
shared between NB and VSD (3q25.32; 399 SNPs, Figure 2A) a d another one shared between NB and
CM (2q35; 28 SNPs, Figure 2B). Two smaller regions were also identified: 12q21.31 has overlapping
association signals in VSD, ASD/PFO, and NB and 14q24.3 has few SNPs which are significant both in
NB and in ToF (Table 3). In this last case the direction of effect of the colocalizing SNPs in both datasets
is the same, supporting a genuine shared allelic risk; whereas in the other cases the direction of effect is
opposite, implying a shared genetic basis [38].
Following recent works that have pointed out the importance of effects mediated by distinct
genetic determinants located in the same genomic regions for informing the causal relationship
between different traits [33,39–41], we also evaluated evidence of this kind of spurious colocalization
between NB and each CHD subtype. On the basis of the physical distance of lead SNPs in significant
loci of association in NB and CHD we identified two colocalizing susceptibility regions: one region
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encompassing band 3q25, colocalizing between NB and ToF (Figure 2C and Table 4), and one further
region in band 4p16.2 in NB and ASD/PFO (Figure S2 and Table 4, empirical p-values < 0.04 and
<0.03, respectively). Table S4 reports all regions in the analyzed datasets with p-value < 10−5 and their
relative distance.
We also used a Bayesian method designed to test whether some genomic regions may harbor
distinct variants associated to multiple traits [33] (see Materials and Methods Section 2.6). We found ten
instances with a posterior probability >0.9 of containing distinct variants associated to NB and one or
more CHD subsets (Table 5). Interestingly some of these identified regions were also identified through
the other approaches although in different CHD subtypes: 2q35 has overlapping association signals
between NB and CM (Figure 2B) and shows evidence of colocalization of NB with DORV and ToF
(Figure 2D,F) and 3q25.32 has overlapping association signals between NB and VSD (Figure 2A) and
shows evidence of colocalization of NB with DORV and ToF (Figure 2C,E). Region 4p16 contains both
a signal of colocalization between NB and ASD/PFO (see above), as well as a signal of colocalization
between NB and DORV. Two further colocalizing regions were identified: 6p22 (colocalizing NB with
CM and NB with DORV) and 11p15 (colocalizing NB with DORV and NB with ToF) (Table 5 and
Figure S2).
3.3. Enrichment in Epigenetic Markers in Colocalizing Regions
Epigenetic features overlapping genetic polymorphisms can help predict in which cell tissue that
variant is likely to act [42]. Therefore we evaluated enrichment of several epigenetic markers from cell
lines and tissues related to neural crest cells, NB, and heart development (see Table S5 for the complete
list) in the set of the most significant SNPs previously identified (i.e., SNPs with p-value < 10−3 in NB
and in at least one CHD subset in the regions reported in Table 3). In order to account for LD structure
and prevent enrichment inflation in case of SNPs residing in high LD blocks, we used the Variant Set
Enrichment (VSE) package from CRAN [34]. Results are shown in Figure 3. It can be seen that few NB
cell lines (NB69, LAN1, BE2C) are significantly enriched in these regions. Interestingly (Table S6), it
can be inferred that 2q35 is an epigenetic hotspot and has signatures from many cell lines whereas
3q25.32 has several epigenetic signatures from adrenal and fetal heart, which are also abundant in 2q35.
The core 15-state model source for epigenomes in HaploReg [35] also gives evidence of enrichment in
fetal heart signatures (p-value = 0.024) in these cross-associated variants.
3.4. Annotation of Colocalizing Regions
We used the genetic variants from the shared (association p-value < 10−3) and distinct (association
p-value < 10−5) colocalizing signals and queried them for eQTL annotation through LinDA (http:
//linda.irgb.cnr.it/). Genes, variants, and tissues are listed in Table 6 and Table S7. This procedure
allows to annotate genes from multiple catalogs that are likely regulated by the list of variants given as
input in a tissue specific manner.
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Table 3. Shared association regions between neuroblastoma and the diverse CHD subtypes.
Disease Band pos hg19 SNPs with
p-value < 10−3 Direction of Effect Lead SNP NB p-value Lead SNP CHD Subtype p-value
CM 2q35 215590505–215840829 28 opposite rs3768708 1.09 × 10−10 rs34206771 7.15 × 10−5
ASD/PFO 12q21.31 85606538–85723868 16 opposite rs7295242 2.75 × 10−4 rs13377665 3.71 × 10−4
VSD 12q21.31 85604092–85723868 18 opposite rs11116772 2.41 × 10−4 rs7954427 5.03 × 10−4
VSD 3q25.32 157828781–158245883 399 opposite rs1978779 6.09 × 10−8 rs6441201 2.39 × 10−5
ToF 14q24.3 79029133–79059667 14 same rs4643247 5.88 × 10−5 rs7159049 7.75 × 10−5
For each region is reported the number of SNPs that have an association p-value below 10−3 in both datasets in that genomic region and the direction of effect, the genomic band, the left
and right margins of this region, and its range in bases, and the lead SNPs in NB and in the CHD subtype with association p-values.
Table 4. Physical distance between lead SNPs in NB and the diverse CHD subtypes.
Band Disease Lead SNP pos hg19 p-value Disease Lead SNP pos hg19 p-value Distance D’ R2
3q25.32 NB rs1978779 158211291 6.09 × 10−8 ToF rs75107964 158458751 1.30 × 10−7 247,460 0.7 0.1
4p16.2 NB rs11944652 4892294 1.61 × 10−6 ASD/PFO rs4689909 4643276 7.75 × 10−7 249,018 0.1 0.01
The table shows only cases in which a lead SNP in a susceptibility locus of NB is less than 250,000 bp away from a lead SNP in a susceptibility locus of at least one CHD subtype.
Table 5. Regions of spurious colocalization between NB and diverse CHD subtypes.
Disease Band pos hg19 Lead SNP NB p-value NB Lead SNP CHD p-value CHD PP
CM 6p22.3 21685357–22748186 rs4712656 6.33 × 10−16 rs147429944 7.39 × 10−9 0.932813
DORV 11p15.4 7436942–8331494 rs204926 6.91 × 10−12 rs12807437 1.71 × 10−3 0.906466
DORV 2q35 215573795–217714948 rs2070096 3.39 × 10−11 rs116515369 2.43 × 10−4 0.91838
DORV 3q25.33 157312429–159477493 rs1978779 6.09 × 10−8 158680170 8.16 × 10−7 0.923649
DORV 4p16.1 8154534–8733618 rs3796727 3.19 × 10−9 chr4:8379187:I 5.06 × 10−3 0.91279
DORV 6p22.3 21685357–22748186 rs4712656 6.33 × 10−16 rs115828798 1.37 × 10−4 0.926876
DORV 6q21 103983460–106054975 rs4945714 1.28 × 10−8 rs78448955 1.44 × 10−3 0.906372
ToF 11p15.4 7436942–8331494 rs204926 6.91 × 10−12 rs6578887 3.80 × 10−5 0.917802
ToF 2q35 215573795–217714948 rs2070096 3.39 × 10−11 rs13023347 5.08 × 10−5 0.919856
ToF 3q25.33 157312429–159477493 rs1978779 6.09 × 10−8 rs75107964 1.30 × 10−7 0.99738
Regions in the table show evidence of association via two distinct variants in NB and in one CHD subtype.
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Figure 3. Box plots represent the distribution of overlap of the epigenetic feature under consideration
with random sets of markers matched to the real set in terms of numerosity and LD structure. The bar
inside each box corresponds to the median enrichment score of the null set. Whiskers span from
minimum value to first quartile and from third quartile to maximum value. Dots represent the estimated
enrichment in the real set of SNPs considered. One feature still significant after stringent multiple
testing correction (Bonferroni corrected p-value < 0.01) is marked in red.
Table 6. eQTL mapping performed in shared and colocalizing susceptibility loci.
Gene Band Number of SNPs
BARD1 2:q35 20
MFSD1 3:q25.32 47
RARRES1 3:q25.32 49
RP11-379F4.4 3:q25.32 47
RP11-538P18.2 3:q25.32 12
RSRC1 3:q25.32 159
SHOX2 3:q25.32 2
HS.276795 4:p16.2 4
MSX1 4:p16.2 1
Genes whose expression is affected by SNPs in identified susceptibility loci common to NB and CHD (see Results
Section 3.4) are shown. Genomic bands and the number of variants analyzed affecting the expression of these genes
is also reported.
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4. Discussion
The evaluation of shared association between epidemiologically linked conditions represents a
powerful tool for the dissection of common and unique mechanisms in the development of phenotypic
traits and the onset of pathological conditions [43,44]. On the basis of possible co-occurrence of NB
and CHD [18,45] and their common derivation from NCC [21,24], we conducted a co-association study
on these conditions, starting from a general evaluation of an excess of shared association signals, to
a more detailed analysis of colocalizing association signals. We observed the strongest evidence of
shared genetic architecture between NB and VSD, both at a genome-wide level (Table 2 and Figure 2)
and at single loci (Tables 3–5), where in band 3q25.32 a region of nearly half Mb harbors 399 SNPs with
association p-value below 10−3 in both conditions, which supports a genuine shared effect. This same
region also shows evidence of shared association between NB and ToF and between NB and DORV.
Most of the SNPs that we identified in these loci of shared association show an opposite allelic
effect. It was reported in the literature that for several conditions with a common pathological basis,
shared genomic loci of association (such as the ones resulting from phenotype cross-trait analysis)
show an opposite effect in several cases, possibly implying opposite functional changes in different
cells/tissues affecting the same molecular trait or pathway [39].
Some of the regions detected by our colocalization analysis include intriguing candidate genes for
NB and CHD. MSX1 (4p16.2) is a homeobox gene involved in neural crest specification [46] that has
been already identified as a CHD susceptibility gene [47]. Our results suggest that common variants
can affect MSX1 expression and can also predispose to NB. The role of MSX1 in NB biology is also
supported by a recent paper that demonstrates a signaling axis leading from PHOX2B via MSX1 to
Delta–Notch and proneural gene expression in NB pathogenesis [48]. Recently, NB has been diagnosed
in a child with Wolf-Hirschhorn syndrome, a congenital disorder with characteristic facial features
caused by microdeletion of the short arm of chromosome 4 encoding the MSX1 gene [49].
Another relevant gene is SHOX2 (3q25.32), a member of the homeobox family which is one of
the major genes involved in the development of the sinoatrial node [50]; its proper function is of
crucial relevance for the origin of arrhythmogenic heart disease [51]. Moreover, SHOX2 is implicated
in specifying neural systems involved in processing somatosensory information, as well as in face and
body structure formation [52,53] and has been reported as involved in Cornelia de Lange syndrome—a
condition that implies heart defects [52,54]. The relevance of this gene is supported from its association
with eQTLs.
Our results and those from the literature show that the aforementioned genes are involved
in developmental processes and that their abnormal functioning due to genetic alterations could
predispose to the development of NB and CHD.
eQTL analysis points out the relevance of loci associated at 3q25.32; in fact 3 genes (MLF1,
RP11-538P18.2, and RSRC1) are associated with variants relevant in at least four conditions: NB,
DORV, ToF, and VSD. MLF1 in particular has been recently described in NB [25] and seems to play an
important role in tumorigenesis. MLF1 is highly expressed in heart and has been identified as a novel
modulator of cardiomyocyte proliferation [55]. Interestingly, our eQTL analysis using data from left
ventricle tissues demonstrates that predisposing NB and CHD variants can affect MLF1 expression.
We found that the known NB susceptibility gene BARD1 (2q35) [4,56] lies in close proximity
to a candidate susceptibility locus for CM; copy number alterations at the BARD1 locus have been
previously associated to developmental delay, coarctation of aorta and ToF [57], suggesting a role of
BARD1 in early organogenesis and heart formation.
The identification of regions of shared susceptibility can help in assigning a hierarchy in the
pathogenic mechanisms of related conditions, and functional and epigenetic characterization of
common associated SNPs from different traits can contribute to single out loci belonging to shared
and unique pathways. Our results suggest a possible common genetic basis between these two NCC
originating conditions. However, larger sample sizes and further studies will be needed to validate
our results and better elucidate the shared genetic risk factors between NB and CHD.
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